Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Discoid Lupus Erythematosus
NCT03866317Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in discoid lupus erythematosus (DLE), sponsored by Massachusetts General Hospital. Primary endpoint: Clinical responder rate at 16 weeks. Planned start Sep 2019; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT03866317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866317.